腹部肥胖和胰岛素抵抗对心脏代谢风险的相互作用影响
Mengyue Lin1, Xiaocong Chen2, Muli Wu2
1Department of Cardiology, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China; Human Phenome Institute of Shantou University Medical College, Guangdong Engineering Research Centre of Human Phenome, Chemistry and Chemical Engineering Guangdong Laboratory, Shantou, Guangdong, China; Clinical Medical Research Center, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
腹部肥胖和胰岛素抵抗预测心脏代谢疾病. 这项研究发现了双向时间联系和对高血压,糖尿病和中风的综合影响,突出了同时进行干预的必要性.
科学领域:
- 心血管健康 心血管健康
- 代谢综合征研究 代谢综合征研究
- 肥胖研究 肥胖研究
背景情况:
- 腹部肥胖 (AO) 和胰岛素抵抗 (IR) 是心脏代谢疾病 (CMD) 的关键预测因素.
- 了解AO和IR的时间关系和综合影响对于预防CMD至关重要.
研究的目的:
- 研究腹部肥胖和胰岛素抵抗之间的时间关系.
- 评估AO和IR对心脏代谢疾病风险的综合影响.
- 评估胰岛素抵抗在AO和CMD之间的关联中的调解作用.
主要方法:
- 一个具有全国代表性的9234名参与者的队列,随访时间长达9年.
- 三甘-葡萄糖 (TyG) 指数用作IR的指标;腰围 (WC) 用于AO.
- 考克斯回归和交叉滞后面板模型分析了组合效应,时间关系和相互作用.
主要成果:
- 同时的AO和高TyG显著增加了高血压,糖尿病和中风的风险.
- 在糖尿病中观察到AO和IR之间的显著生物相互作用.
- 在WC和TyG之间存在着双向的时间关系,WC对TyG的影响更大.
结论:
- 在腹部肥胖和胰岛素抵抗之间存在时间关系.
- 联合AO和IR显著增加高血压,糖尿病和中风的风险.
- 胰岛素抵抗调解了AO对高血压,糖尿病和中风的影响,强调了CMD预防的双重向策略.
更多相关视频
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
08:22Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion
Published on: March 20, 2017
相关概念视频
Obesity
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Type 2 and Gestational
